T1	Participants 66 88	small-cell lung cancer
T2	Participants 287 377	previously untreated patients with extensive-stage small-cell carcinoma of the lung (SCLC)
T3	Participants 400 545	Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50 and adequate renal function and bone marrow reserve were eligible
T4	Participants 947 992	rom May 1989 through March 1993, 171 patients
